Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. 1995 Mar; 146(3): 695–705.
PMCID: PMC1869171

Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop.


The neuroendocrine hormone prolactin is a growth factor required for the proliferation and terminal differentiation of the human breast. These effects are mediated by the prolactin receptor, a member of the growth factor receptor family. Three prolactin receptor isoforms (long, intermediate, and short) have been identified in the rat, which differ in the length of their intracytoplasmic domains. In humans, however, only the long prolactin receptor isoform had been identified previously. The expression of the human intermediate prolactin receptor is demonstrated and preliminary evidence for a human short isoform is presented. Heterogeneous expression of prolactin receptor, at the immunoblot and immunohistochemical levels was observed in breast carcinoma specimens. A statistically significant correlation between prolactin receptor and estrogen receptor expression was noted. An autocrine/paracrine role for prolactin within breast tissues was further examined by performing reverse transcription polymerase chain reaction on RNA isolated from cell lines and clinical specimens with prolactin-specific primers. A 585-bp product was observed and found to be identical to human prolactin. The synthesis of prolactin by breast epithelium was confirmed by in situ hybridization analysis of breast tissues and the detection of bio- and immunoreactive prolactin in breast cancer lines. These analyses indicate that the principal site for prolactin expression within the normal or malignant breast residues within the epithelium. These data indicate that prolactin may participate in an autocrine/paracrine stimulatory loop within breast tissues and suggest a role for this growth factor in the pathogenesis of breast cancer.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cunningham BC, Henner DJ, Wells JA. Engineering human prolactin to bind to the human growth hormone receptor. Science. 1990 Mar 23;247(4949 Pt 1):1461–1465. [PubMed]
  • Wells JA, Cunningham BC, Fuh G, Lowman HB, Bass SH, Mulkerrin MG, Ultsch M, deVos AM. The molecular basis for growth hormone-receptor interactions. Recent Prog Horm Res. 1993;48:253–275. [PubMed]
  • Ormandy CJ, Sutherland RL. Mechanisms of prolactin receptor regulation in mammary gland. Mol Cell Endocrinol. 1993 Feb;91(1-2):C1–C6. [PubMed]
  • Kelly PA, Ali S, Rozakis M, Goujon L, Nagano M, Pellegrini I, Gould D, Djiane J, Edery M, Finidori J, et al. The growth hormone/prolactin receptor family. Recent Prog Horm Res. 1993;48:123–164. [PubMed]
  • Shiu RP, Iwasiow BM. Prolactin-inducible proteins in human breast cancer cells. J Biol Chem. 1985 Sep 15;260(20):11307–11313. [PubMed]
  • Guyette WA, Matusik RJ, Rosen JM. Prolactin-mediated transcriptional and post-transcriptional control of casein gene expression. Cell. 1979 Aug;17(4):1013–1023. [PubMed]
  • Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, Banville D, Dusanter-Fourt I, Djiane J, Kelly PA. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell. 1988 Apr 8;53(1):69–77. [PubMed]
  • Shirota M, Banville D, Ali S, Jolicoeur C, Boutin JM, Edery M, Djiane J, Kelly PA. Expression of two forms of prolactin receptor in rat ovary and liver. Mol Endocrinol. 1990 Aug;4(8):1136–1143. [PubMed]
  • Ali S, Pellegrini I, Kelly PA. A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. J Biol Chem. 1991 Oct 25;266(30):20110–20117. [PubMed]
  • Boutin JM, Edery M, Shirota M, Jolicoeur C, Lesueur L, Ali S, Gould D, Djiane J, Kelly PA. Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol Endocrinol. 1989 Sep;3(9):1455–1461. [PubMed]
  • Lesueur L, Edery M, Ali S, Paly J, Kelly PA, Djiane J. Comparison of long and short forms of the prolactin receptor on prolactin-induced milk protein gene transcription. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):824–828. [PMC free article] [PubMed]
  • Shiu RP, Murphy LC, Tsuyuki D, Myal Y, Lee-Wing M, Iwasiow B. Biological actions of prolactin in human breast cancer. Recent Prog Horm Res. 1987;43:277–303. [PubMed]
  • Costlow ME, Buschow RA, Richert NJ, McGuire WL. Prolactin and estrogen binding in transplantable hormone-dependent and autonomous rat mammary carcinoma. Cancer Res. 1975 Apr;35(4):970–974. [PubMed]
  • Manni A, Trujillo JE, Pearson OH. Predominant role of prolactin in stimulating the growth of 7, 12-dimethylbenz(a)anthracene-induced rat mammary tumor. Cancer Res. 1977 Apr;37(4):1216–1219. [PubMed]
  • Peyrat JP, Vennin P, Bonneterre J, Hecquet B, Vandewalle B, Kelly PA, Djiane J. Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer. Eur J Cancer Clin Oncol. 1984 Nov;20(11):1363–1367. [PubMed]
  • Clinical trial of 2-Br- -ergocryptine (CB154) in advanced breast cancer. Eur J Cancer. 1972 Apr;8(2):155–156. [PubMed]
  • Welsch CW, Aylsworth CF. Enhancement of murine mammary tumorigenesis by feeding high levels of dietary fat: a hormonal mechanism? J Natl Cancer Inst. 1983 Feb;70(2):215–221. [PubMed]
  • Ingram DM, Nottage EM, Roberts AN. Prolactin and breast cancer risk. Med J Aust. 1990 Oct 15;153(8):469–473. [PubMed]
  • Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992 Jul;6(7):1023–1031. [PubMed]
  • O'Neal KD, Montgomery DW, Truong TM, Yu-Lee LY. Prolactin gene expression in human thymocytes. Mol Cell Endocrinol. 1992 Sep;87(1-3):R19–R23. [PubMed]
  • Clevenger CV, Altmann SW, Prystowsky MB. Requirement of nuclear prolactin for interleukin-2--stimulated proliferation of T lymphocytes. Science. 1991 Jul 5;253(5015):77–79. [PubMed]
  • Clevenger CV, Sillman AL, Hanley-Hyde J, Prystowsky MB. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 1992 Jun;130(6):3216–3222. [PubMed]
  • Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. [PubMed]
  • Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6460–6464. [PMC free article] [PubMed]
  • Montone KT, Tomaszewski JE. In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J Clin Lab Anal. 1993;7(3):188–195. [PubMed]
  • Montone KT, Friedman H, Hodinka RL, Hicks DG, Kant JA, Tomaszewski JE. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder. Mod Pathol. 1992 May;5(3):292–302. [PubMed]
  • Iezzoni JC, Kang JH, Montone KT, Reed JA, Brigati DJ. Colorimetric detection of herpes simplex virus by DNA in situ sandwich hybridization: a rapid, formamide-free, random oligomer-enhanced method. Nucleic Acids Res. 1992 Mar 11;20(5):1149–1150. [PMC free article] [PubMed]
  • Bonneterre J, Peyrat JP, Beuscart R, Lefebvre J, Demaille A. Prognostic significance of prolactin receptors in human breast cancer. Cancer Res. 1987 Sep 1;47(17):4724–4728. [PubMed]
  • De Placido S, Gallo C, Perrone F, Marinelli A, Pagliarulo C, Carlomagno C, Petrella G, D'Istria M, Delrio G, Bianco AR. Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. Br J Cancer. 1990 Oct;62(4):643–646. [PMC free article] [PubMed]
  • Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Correlation between prolactin receptors (PRL R), estradiol (ER) and progesterone receptors (PgR) in human breast cancer. Eur J Cancer Clin Oncol. 1986 Nov;22(11):1331–1336. [PubMed]
  • Turcot-Lemay L, Kelly PA. Prolactin receptors in human breast tumors. J Natl Cancer Inst. 1982 Mar;68(3):381–383. [PubMed]
  • Murphy LJ, Murphy LC, Vrhovsek E, Sutherland RL, Lazarus L. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res. 1984 May;44(5):1963–1968. [PubMed]
  • Manni A, Wright C, Davis G, Glenn J, Joehl R, Feil P. Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay. Cancer Res. 1986 Apr;46(4 Pt 1):1669–1672. [PubMed]
  • Malarkey WB, Kennedy M, Allred LE, Milo G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab. 1983 Apr;56(4):673–677. [PubMed]
  • Mansfield CM. A review of the etiology of breast cancer. J Natl Med Assoc. 1993 Mar;85(3):217–221. [PMC free article] [PubMed]
  • Biswas R, Vonderhaar BK. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res. 1987 Jul 1;47(13):3509–3514. [PubMed]
  • Venkitaraman AR, Cowling RJ. Interleukin 7 receptor functions by recruiting the tyrosine kinase p59fyn through a segment of its cytoplasmic tail. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12083–12087. [PMC free article] [PubMed]
  • Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem. 1994 Feb 18;269(7):5364–5368. [PubMed]
  • Clevenger CV, Torigoe T, Reed JC. Prolactin induces rapid phosphorylation and activation of prolactin receptor-associated RAF-1 kinase in a T-cell line. J Biol Chem. 1994 Feb 25;269(8):5559–5565. [PubMed]
  • Clevenger CV, Medaglia MV. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Mol Endocrinol. 1994 Jun;8(6):674–681. [PubMed]
  • Holdaway IM, Friesen HG. Hormone binding by human mammary carcinoma. Cancer Res. 1977 Jul;37(7 Pt 1):1946–1952. [PubMed]
  • Ormandy CJ, Clarke CL, Kelly PA, Sutherland RL. Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells. Int J Cancer. 1992 Mar 12;50(5):777–782. [PubMed]
  • Ormandy CJ, de Fazio A, Kelly PA, Sutherland RL. Coordinate regulation of oestrogen and prolactin receptor expression by sodium butyrate in human breast cancer cells. Biochem Biophys Res Commun. 1992 Jan 31;182(2):740–745. [PubMed]
  • Simon WE, Pahnke VG, Hölzel F. In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. J Clin Endocrinol Metab. 1985 Jun;60(6):1243–1249. [PubMed]
  • Appleby MW, Gross JA, Cooke MP, Levin SD, Qian X, Perlmutter RM. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. 1992 Sep 4;70(5):751–763. [PubMed]
  • Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11538–11542. [PMC free article] [PubMed]
  • Fuqua SA, Chamness GC, McGuire WL. Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993 Feb;51(2):135–139. [PubMed]
  • Sluyser M. Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin Biochem. 1992 Dec;25(6):407–414. [PubMed]
  • Rose DP, Pruitt BT. Plasma prolactin levels in patients with breast cancer. Cancer. 1981 Dec 15;48(12):2687–2691. [PubMed]
  • Biswas R, Vonderhaar BK. Tamoxifen inhibition of prolactin action in the mouse mammary gland. Endocrinology. 1991 Jan;128(1):532–538. [PubMed]
  • Biswas R, Vonderhaar BK. Antiestrogen inhibition of prolactin-induced growth of the Nb2 rat lymphoma cell line. Cancer Res. 1989 Nov 15;49(22):6295–6299. [PubMed]
  • Das RB, Biswas R, Vonderhaar BK. Characteristics of a membrane-associated antilactogen binding site for tamoxifen. Mol Cell Endocrinol. 1993 Dec;98(1):1–8. [PubMed]
  • Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, Kooijman R, Kutz L, Kelley KW, Malarkey WB. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7713–7716. [PMC free article] [PubMed]
  • DiMattia GE, Gellersen B, Bohnet HG, Friesen HG. A human B-lymphoblastoid cell line produces prolactin. Endocrinology. 1988 Jun;122(6):2508–2517. [PubMed]
  • Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest. 1993 Mar;68(3):354–360. [PubMed]
  • Kurtz A, Bristol LA, Tóth BE, Lazar-Wesley E, Takács L, Kacsóh B. Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. Biol Reprod. 1993 May;48(5):1095–1103. [PubMed]
  • Steinmetz RW, Grant AL, Malven PV. Transcription of prolactin gene in milk secretory cells of the rat mammary gland. J Endocrinol. 1993 Feb;136(2):271–276. [PubMed]
  • Markoff E, Sigel MB, Lacour N, Seavey BK, Friesen HG, Lewis UJ. Glycosylation selectively alters the biological activity of prolactin. Endocrinology. 1988 Sep;123(3):1303–1306. [PubMed]
  • Liu JH, Lee DW, Markoff E. Differential release of prolactin variants in postpartum and early follicular phase women. J Clin Endocrinol Metab. 1990 Sep;71(3):605–610. [PubMed]
  • Gonnella PA, Harmatz P, Walker WA. Prolactin is transported across the epithelium of the jejunum and ileum of the suckling rat. J Cell Physiol. 1989 Jul;140(1):138–149. [PubMed]
  • Berczi I, Nagy E, Kovacs K, Horvath E. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol (Copenh) 1981 Dec;98(4):506–513. [PubMed]
  • Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 1988 Jan 22;239(4838):401–404. [PubMed]
  • Hartmann DP, Holaday JW, Bernton EW. Inhibition of lymphocyte proliferation by antibodies to prolactin. FASEB J. 1989 Aug;3(10):2194–2202. [PubMed]
  • Nagy E, Berczi I, Wren GE, Asa SL, Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology. 1983 Oct;6(3):231–243. [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...